Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Scientists create 3D image of key protein involved in blood and other cancer development

Scientists at the Walter and Eliza Hall Institute have created the first three-dimensional image of a key protein known to be involved in the development of blood and other cancers.

13 Oct 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Study reveals how leukemia cells evade deadly effects of BRD4 inhibitors

BRD4 inhibitors are among the most promising new agents in cancer therapy that are currently evaluated in clinical trials.

15 Sep 2015

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.

11 Sep 2015

Researchers identify new way to help AML patients avoid a relapse

A protein domain once considered of little importance may be key to helping patients who are fighting acute myeloid leukemia (AML) avoid a relapse.

8 Sep 2015

Treating cancer cells with quizartinib inhibits key metabolic pathway, activates macroautophagy

A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

1 Sep 2015

Persistent leukemia-associated genetic mutations linked to increased risk of relapse, reduced overall survival

In preliminary research, the detection of persistent leukemia-associated genetic mutations in at least 5 percent of bone marrow cells in day 30 remission samples among adult patients with acute myeloid leukemia was associated with an increased risk of relapse and reduced overall survival, according to a study in the August 25 issue of JAMA.

26 Aug 2015

Lingering cancer-related mutations linked to increased risk of relapse, poor survival in leukemia patients

For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and poor survival.

26 Aug 2015

Newly developed big data technique may have significant impact on health care

Rice University scientists have developed a big data technique that could have a significant impact on health care. The Rice lab of bioengineer Amina Qutub designed an algorithm called "progeny clustering" that is being used in a hospital study to identify which treatments should be given to children with leukemia.

13 Aug 2015

New study reveals protein's critical role in development and progression of AML

A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.

24 Jul 2015

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $875,000 to help address a critical shortage of funding for pediatric cancer research.

10 Jul 2015

ExCellThera's stem cell expansion approach may benefit AML patients undergoing transplants

Patients suffering from acute myeloid leukemia, who require stem cell transplantation as part of their treatment,may now benefit from a new best-in-class process that improves the viability and success of cord blood stem cell transplantation.

18 Jun 2015

Molecules derived from avocados could help combat acute myeloid leukemia

Rich, creamy, nutritious and now cancer fighting. New research reveals that molecules derived from avocados could be effective in treating a form of cancer.

16 Jun 2015

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR).

15 Jun 2015

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.

10 Jun 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.